nach oben

Current Rheumatology Reports

Erschienen in:

01.12.2014 | Inflammatory Muscle Disease (RG Cooper, Section Editor)

Myositis Specific and Associated Autoantibodies in the Diagnosis and Management of Juvenile and Adult Idiopathic Inflammatory Myopathies

verfasst von: Sarah L. Tansley, Neil J. McHugh

Erschienen in: Current Rheumatology Reports | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

The idiopathic inflammatory myopathies are a heterogeneous group of disorders affecting both adults and children. Clinical features can include muscle weakness, skin disease and internal organ involvement. A large number of autoantibodies, directed against cytoplasmic or nuclear components, can now be identified in these patients and specific clinic-serological syndromes have been described. Laboratory testing to identify many of these autoantibodies is becoming easier, and here we discuss the clinical utility of autoantibodies in myositis both in terms of facilitating diagnosis, predicting disease course and informing management decisions.

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012;14(2):R97.PubMedCentralPubMedCrossRef

Bendewald MJ, Wetter DA, Li X, Davis MDP. Incidence of Dermatomyositis and Clinically Amyopathic Dermatomyositis. Arch Dermatol. 2010;146(1):26–30.PubMedCrossRef

Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol. 2010;22(6):639–43.PubMedCrossRef

Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri S, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology. 2012;51(7):1278–84.PubMedCrossRef

Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49(9):1713–9.PubMedCrossRef

Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. 2012;12(2):210–7.PubMedCrossRef

Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve. 2000;23(6):970–2.PubMedCrossRef

Needham M, James I, Corbett A, Day T, Christiansen F, Phillips B, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry. 2008;79(9):1056–60.PubMedCrossRef

Pilkington C, Tjarnlund A, Bottai M, Rider LG, Werth VP, de Visser M, et al. A47: progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies. Arthr Rheumatol. 2014;66 Suppl 11:S70–1.CrossRef

10.

Kang EH, Kuwana M, Okazaki Y, Lee EY, Lee YJ, Lee EB, et al. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients. Mod Rheumatol. 2014.

11.

Musset L, Miyara M, Benveniste O, Charuel J-L, Shikhman A, Boyer O, et al. Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies. J Immunol Res. 2014. doi:10.1155/2014/405956.

12.

Drouot L, Allenbach Y, Jouen F, Charuel J-L, Martinet JRM, Meyer A, et al. Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3- methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther. 2014;16(1):1–11.CrossRef

13.

Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, et al. The Multicenter Study of a New Assay for Simultaneous Detection of Multiple Anti-Aminoacyl-tRNA Synthetases in Myositis and Interstitial Pneumonia. Kuwana M, editor. PLoS ONE. 2014;9(1):e85062.PubMedCentralPubMedCrossRef

14.

Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-TIF1 antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis. 2012;71(6):993–6.

15.•

Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol. 2012;24(6):602–8. A comprehensive review of autoantibodies in myositis and their associated phenotype including autoimmune necrotising myositis.PubMedCrossRef

16.

Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48(6):607–12.PubMedCrossRef

17.

Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, et al. Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome. Miller F, editor. PLoS ONE. 2013;8(4):e60442.PubMedCentralPubMedCrossRef

18.

Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011;105(8):1238–47.PubMedCrossRef

19.•

20.•

Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2013. A comparison of survival of a cohort of patients with and without anti-synthetase autoantibodies.

21.

Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res. 2014;66(5):732–40.CrossRef

22.

Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56(9):3132–7.PubMedCrossRef

23.

Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity. 2013;46(4):279–84.PubMedCrossRef

24.

Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods. 2012;384(1–2):128–34.PubMedCrossRef

25.

Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WER, Cooper RG, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68(10):1621–5.

26.

Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.PubMedCentralPubMedCrossRef

27.

Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–200.PubMedCrossRef

28.

Hall JC, Casciola-Rosen L, Samedy L-A, Werner J, Owoyemi K, Danoff SK, et al. Anti-MDA5-associated dermatomyositis: Expanding the clinical spectrum. Arthritis Care Res. 2013;65(8):1307–15.CrossRef

29.

Bendewald MJ. Incidence of Dermatomyositis and Clinically Amyopathic DermatomyositisA Population-Based Study in Olmsted County. Minnesota. Arch Dermatol. 2010;146(1):26.PubMedCrossRef

30.

Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157(4):637–44.PubMedCrossRef

31.

Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138.PubMedCentralPubMedCrossRef

32.

Kobayashi I, Okura Y, Yamada H. Anti-Melanoma Differentiation-Associated Gene 5 Antibody is a Diagnostic and Predictive Marker for Interstitial Lung Diseases Associated with Juvenile Dermatomyositis. J Pediatr. 2011;158(4):675–7.PubMedCrossRef

33.

Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol. 2011;23(6):612–9.PubMedCrossRef

34.

Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21.PubMedCentralPubMedCrossRef

35.

Amato AA, Gronseth GS, Jackson CE, Wolfe GI, Katz JS, Bryan WW, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996;40(4):581–6.PubMedCrossRef

36.

Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open. 2014;1–14.

37.

Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa Muscle Protein in Inclusion Body Myositis. Chiorini JA, editor. PLoS ONE. 2011;6(5):e20266.PubMedCentralPubMedCrossRef

38.

Pluk H, van Engelen BG, Pruijn GJM. Anti-Mup44: the first inclusion body myositis-specific autoantibody. Autoantigens, Autoantibodies. Autoimmunity. 2011;7:210.

39.

Pluk H, van Hoeve BJA, van Dooren SHJ, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397–407.PubMedCrossRef

40.

Benjamin Larman H, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73(3):408–18.PubMedCrossRef

41.•

Greenberg SA. Cytoplasmic 5′-Nucleotidase Autoantibodies in Inclusion Body Myositis: Isotypes and Diagnostic Utility. Muscle Nerve. 2014. doi:10.1002/mus.24199. An exploration of the utility of different tests for cytoplasmic 5′-nucleotidase 1A autoantibody isotypes suggests a high diagnostic sensitivity.

42.

Aguila LA, Lopes MRU, Pretti FZ, Sampaio-Barros PD, Carlos de Souza FH, Borba EF, et al. Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. Clin Rheumatol. 2014;33(8):1093–8.PubMedCrossRef

43.

Koschik RW, Fertig N, Lucas MR, Domsic RT, Medsger TAJ. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):S12–6.PubMed

44.

Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, Danko K, Vencovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine. 2012;91(4):206–11.PubMedCrossRef

45.

Rutjes SA, Vree Egberts WTM, Jongen P, Van Den Hoogen F, Pruijn GJM, van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 1997;109:32–40.PubMedCentralPubMedCrossRef

46.

Brouwer R, Hengstman GJD, Vree Egberts WTM, Ehrfeld H, Bozic B, Ghiradello A, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001;60:116–23.

47.

Váncsa A, Csípő I, Németh J, Dévényi K, Gergely L, Dankó K. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int. 2009;29(9):989–94.

48.

La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39(3):249–53.

49.

Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, et al. Short-Term and Long-Term Outcome of Anti-Jo1-Positive Patients with Anti-Ro52 Antibody. Semin Arthritis Rheum. 2012;41(6):890–9.PubMedCrossRef

50.

McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)–clinical characteristics of children recruited within the first 5 yr. Rheumatology. 2006;45(10):1255–60.PubMedCrossRef

51.

Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100.PubMedCrossRef

52.

Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–32.PubMedCrossRef

53.

Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2013;71(5):710–3.

54.

Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology. 2007;47(3):324–8.CrossRef

55.

Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology. 2014.

56.

Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010;49(3):433–40.PubMedCrossRef

57.

Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571–6.PubMedCrossRef

58.

Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1- antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010;49(9):1726–33.PubMedCrossRef

59.

Kobayashi I. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology. 2002;42(2):371–4.CrossRef

60.

Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology. 2012;51(5):800–4.PubMedCrossRef

61.

Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 2012;51(9):1563–70.PubMedCrossRef

62.

Sato S, Kobayashi N, Yamazaki K, Suzuki Y. Clinical Utility of Anti-CADM-140/Melanoma differentiation-associated gene 5 autoantibody titres in patients with juvenile dermatomyositis and rapidly progressive interstitial lung disease [abstract]. Arthritis Rheum. 2012;64(10):S128.

63.

Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of Interstitial Lung Diseases. Mayo Clin Proc. 2007;62(8):976–86.CrossRef

64.

Huber AM, Feldman BM. Medium and long term functional outcomes in a mulitcenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541–9.PubMedCrossRef

65.

Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60(11):3425–35.PubMedCentralPubMedCrossRef

66.

Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity. Medicine. 2008;87(2):70–86.PubMedCentralPubMedCrossRef

67.

Gordon PA, Winer JB, Hoogendijk JE, Choy EHS. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD003643. doi:10.1002/14651858.CD003643.pub4.

68.•

Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66(3):740–9. An analysis of patients participating in the RIM study which indicates a differential response to Rituximab dependant on autoantibody status.PubMedCrossRef

69.

Unger L, Kampf S, Luthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology. 2014;53(9):1630–8.PubMedCrossRef

Titel: Myositis Specific and Associated Autoantibodies in the Diagnosis and Management of Juvenile and Adult Idiopathic Inflammatory Myopathies
verfasst von: Sarah L. Tansley
Neil J. McHugh
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 12/2014
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-014-0464-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

Enthesitis-Related Arthritis: Time to Re-define?

Amyopathic Dermatomyositis: Definitions, Diagnosis, and Management

Economics of Stratified Medicine in Rheumatoid Arthritis

The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis